[go: up one dir, main page]

WO2007047489A3 - Compositions et procedes utilises dans le traitement du cancer - Google Patents

Compositions et procedes utilises dans le traitement du cancer Download PDF

Info

Publication number
WO2007047489A3
WO2007047489A3 PCT/US2006/040183 US2006040183W WO2007047489A3 WO 2007047489 A3 WO2007047489 A3 WO 2007047489A3 US 2006040183 W US2006040183 W US 2006040183W WO 2007047489 A3 WO2007047489 A3 WO 2007047489A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
rtk
compositions
cancer therapy
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040183
Other languages
English (en)
Other versions
WO2007047489A2 (fr
Inventor
Mark Brann
Hans Schiffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Publication of WO2007047489A2 publication Critical patent/WO2007047489A2/fr
Publication of WO2007047489A3 publication Critical patent/WO2007047489A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions destinées à coadministrer un inhibiteur RTK et un ligand RTK. L'invention concerne également des procédés destinés à réduire un effet indésirable dû à l'administration d'un inhibiteur RTK par coadministration d'un inhibiteur RTK et d'un ligand RTK. L'invention concerne enfin des procédés destinés à informer un sujet que la coadministration d'un inhibiteur RTK et d'un ligand RTK réduit un effet indésirable dû à l'administration d'un inhibiteur RTK.
PCT/US2006/040183 2005-10-18 2006-10-16 Compositions et procedes utilises dans le traitement du cancer Ceased WO2007047489A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72796305P 2005-10-18 2005-10-18
US60/727,963 2005-10-18

Publications (2)

Publication Number Publication Date
WO2007047489A2 WO2007047489A2 (fr) 2007-04-26
WO2007047489A3 true WO2007047489A3 (fr) 2007-06-21

Family

ID=37836870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040183 Ceased WO2007047489A2 (fr) 2005-10-18 2006-10-16 Compositions et procedes utilises dans le traitement du cancer

Country Status (1)

Country Link
WO (1) WO2007047489A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101116868B1 (ko) * 2008-10-20 2012-02-29 성균관대학교산학협력단 안질환의 예방 또는 치료용 조성물
WO2011054359A2 (fr) * 2009-11-06 2011-05-12 University Of Copenhagen Méthode de détection précoce du cancer
WO2015000921A1 (fr) * 2013-07-01 2015-01-08 Fondazione Centro San Raffaele Activateurs de la voie ptgds et utilisation dans des pathologies caractérisées par une altération de la myélinisation dans le snc
JP2017516783A (ja) * 2014-05-29 2017-06-22 デウン ファーマシューティカル カンパニー リミテッド 皮膚発疹の予防用または治療用の医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
WO2007047489A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2011091305A3 (fr) Inhibition de la signalisation axl dans une thérapie antimétastasique
WO2009039460A3 (fr) Co-administration de pimavansérine avec d'autres agents
WO2015095819A3 (fr) Traitement du cancer faisant appel à des associations d'inhibiteurs de l'erk et de la raf
WO2005070930A3 (fr) Composes de tetrahydrocarboline comme agents anticancereux
HK1198869A1 (en) Combination treatments for hepatitis c
WO2007101224A3 (fr) Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation
EP2671584A3 (fr) Compositions et procédés pour traiter des troubles associés à la rétention de sel ou de fluide
WO2016133903A3 (fr) Polythérapie pour le traitement du cancer
WO2009002867A3 (fr) Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
WO2006089150A3 (fr) Agents anti-angiogeniques comportant de l'aldesleukine
MY173215A (en) Acetylcysteine compositions and methods of use thereof
WO2015095834A3 (fr) Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2
WO2010121164A3 (fr) Composés de 1,4-benzodiazépinone et leur utilisation dans le traitement du cancer
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2010136168A8 (fr) Administration continue de ligands d'intégrines pour le traitement du cancer
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2012135528A3 (fr) Polythérapie par galectine-3c pour cancer humain
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2007130501A3 (fr) Polythérapie pour traiter le cancer
WO2008052054A3 (fr) Synergie entre des cellules immunes activées et des thérapies contre le cancer classiques
ATE498427T1 (de) Therapeutische kombinationen
SI1803456T1 (sl) Farmacevtski sestavki, ki obsegajo L-733060, za uporabo pri zdravljenju rakavih tumorjev
WO2007047489A3 (fr) Compositions et procedes utilises dans le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 06816918

Country of ref document: EP

Kind code of ref document: A2